Now, it is Alexion's turn. Elliott, frustrated by the biotech's lagging share price, decided last year it wanted Alexion to go on the block. This power struggle came to light in December. That's when Alexion issued a statement rebuffing Elliott, saying a sale process would not be in the best interest of shareholders or patients. Alexion's stock now trades around $102 a share, down from around $108 at the start of the year, after plummeting into the $70 range two months ago. The most recent closing price values Alexion at some $22.5 billion.